<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01495676</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG V04</org_study_id>
    <secondary_id>2011-000408-17</secondary_id>
    <nct_id>NCT01495676</nct_id>
  </id_info>
  <brief_title>A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer</brief_title>
  <acronym>GETUGV04</acronym>
  <official_title>A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If radical cystectomy remains the standard of care for muscle invasive bladder cancer,&#xD;
      consequences of this surgical procedure are often harsh. Over the past years, concurrent&#xD;
      chemo-radiotherapy has imposed itself as an alternative treatment. Published data on&#xD;
      concomitant radiochemotherapy (radiotherapy/cisplatin or&#xD;
      radiotherapy/cisplatin/5-fluorouracil combinations) showed local control rates with bladder&#xD;
      preservation at 5 years ranging from 40% to 65% according to the disease stage, and overall&#xD;
      survival probabilities ranging from 40% to 50% at 5 years. In order to improve local and&#xD;
      systemic prognosis, evaluation of other chemotherapy agents with higher radiosensitizing&#xD;
      effect, such as gemcitabine, is justified. Gemcitabine possesses its own anti-cancer&#xD;
      activities on urothelial diseases and has a synergetic activity with cisplatin. The&#xD;
      investigators completed a monocenter phase I study combining radiotherapy, cisplatin, and&#xD;
      twice-weekly gemcitabine, and determined a recommended dose of gemcitabine 25 mg/m². The&#xD;
      objective of the present study is to evaluate the combination of radiotherapy + cisplatin +&#xD;
      gemcitabine in terms of disease-free survival in non metastatic muscle invasive urothelial&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the present study is to evaluate the combination of radiotherapy + cisplatin&#xD;
      + gemcitabine in terms of disease-free survival in non metastatic muscle invasive urothelial&#xD;
      cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Two years after the end of the complete therapeutic sequence</time_frame>
    <description>The time to relapse is defined as the time from the date of randomisation to the date of the first event. Time to relapse for patients without any event (local, regional, distance, or death) will be censored at the date of latest information.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The time to death is defined as time from the randomization to the date of death from any cause, or to the date on which latest information is obtained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Acute and late toxicities will be scored according to the NCI-CTC v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measurement of Quality of life</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Questionnaires QLQ C30 + QLQ-BLM30 + QLQ-ELD15 + Oncodage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between lymphocyte apoptosis and severity of late toxicities.</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Before starting radiotherapy, 5ml of blood will be sampled in a 5ml heparinised tube to prospectively measure the rate of CD8 radio-induced lymphocyte apoptosis before any radiotherapy treatment. A correlation between the low rate of lymphocyte apoptosis and the severity of late toxicities will be studied to confirm the predictive power of this biological test on radio-induced side-effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Infiltrating Bladder Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Radiotherapy + cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy + cisplatin + gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiation + cisplatin</intervention_name>
    <description>RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.&#xD;
Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.&#xD;
A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.&#xD;
In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.&#xD;
In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study.</description>
    <arm_group_label>Radiotherapy + cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiation + cisplatin + gemcitabine</intervention_name>
    <description>Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.&#xD;
Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.&#xD;
Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection.</description>
    <arm_group_label>Radiotherapy + cisplatin + gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Muscle invasive urothelial cancer (front line or following the progression of a&#xD;
             superficial tumor), pT2-pT3 stage without lymphatic impairment (N0) and without&#xD;
             detectable metastases (M0). An optimal macroscopic resection (TURB) have to be&#xD;
             performed&#xD;
&#xD;
          -  The proof of invasive tumor to the muscle should be brought by a transurethral&#xD;
             resection under anaesthesia less than 8 weeks before or, in the absence, by&#xD;
             superficial biopsies and formal imaging. Multiples biopsies in the bladder must also&#xD;
             be performed.&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  Kanorfsky index ≥ 70 % (WHO 0, 1, 2)&#xD;
&#xD;
          -  Biological criteria: neutrophils ≥ 1500/mm3, Platelets ≥ 100 000/mm3, haemoglobin ≥ 10&#xD;
             g/dl, creatinine clearance &gt; 60 ml/mn&#xD;
&#xD;
          -  No distant metastases (Thorax, abdomen, and pelvic CT-scan, bone scan)&#xD;
&#xD;
          -  Efficient contraception for premenopausal women, maintained during the whole treatment&#xD;
             and up to two months after the completion of radiotherapy.&#xD;
&#xD;
          -  No radiotherapy or chemotherapy history except for in situ bladder lesions.&#xD;
&#xD;
          -  No carcinological history except for non melanoma skin tumours, in situ uterine cervix&#xD;
             cancer&#xD;
&#xD;
          -  No contraindication to gemcitabine or cisplatin.&#xD;
&#xD;
          -  No contraindication to radiotherapy&#xD;
&#xD;
          -  Information letter and informed consent signed&#xD;
&#xD;
          -  Patient covered by social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bladder tumors without any muscle infiltration&#xD;
&#xD;
          -  Epidermoid carcinoma or adenocarcinoma&#xD;
&#xD;
          -  Distance metastases or extrapelvic node positivity&#xD;
&#xD;
          -  Severe digestive history (ulcerative colitis, complicated diverticulitis)&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre BLEUSE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ICM Val d'Aurelle</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Azria, MD., Ph D</last_name>
    <phone>+33 4 67 61 31 35</phone>
    <email>David.Azria@montpellier.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Pierre BLEUSE, MD</last_name>
    <phone>+33467613102</phone>
    <email>jean-pierre.bleuse@icm.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle-Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Bleuse, MD</last_name>
      <phone>+33 4 67 61 23 44</phone>
      <email>Jean-Pierre.Bleuse@montpellier.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>David Azria, MD, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Azria D, Jacot W, Prost P, Culine S, Ychou M, Lemanski C, Dubois JB. [Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination]. Bull Cancer. 2002 Apr;89(4):369-79. Review. French.</citation>
    <PMID>12016038</PMID>
  </reference>
  <reference>
    <citation>Caffo O, Fellin G, Graffer U, Valduga F, Bolner A, Luciani L, Tomio L, Galligioni E. Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1310-6.</citation>
    <PMID>14630267</PMID>
  </reference>
  <reference>
    <citation>Chauvet B, Brewer Y, Félix-Faure C, Davin JL, Choquenet C, Reboul F. Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy. J Urol. 1996 Oct;156(4):1258-62.</citation>
    <PMID>8808849</PMID>
  </reference>
  <reference>
    <citation>Chauvet B, Davin JL, Alfonsi M, Berger C, Vincent P, Reboul F. [Conservative treatment of bladder cancers with radiotherapy and concurrent chemotherapy: results and perspectives]. Cancer Radiother. 1998 Sep-Oct;2(5):499-504. Review. French.</citation>
    <PMID>9868392</PMID>
  </reference>
  <reference>
    <citation>Choudhury A, Swindell R, Logue JP, Elliott PA, Livsey JE, Wise M, Symonds P, Wylie JP, Ramani V, Sangar V, Lyons J, Bottomley I, McCaul D, Clarke NW, Kiltie AE, Cowan RA. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011 Feb 20;29(6):733-8. doi: 10.1200/JCO.2010.31.5721. Epub 2011 Jan 4.</citation>
    <PMID>21205754</PMID>
  </reference>
  <reference>
    <citation>Dunst J, Sauer R, Schrott KM, Kühn R, Wittekind C, Altendorf-Hofmann A. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys. 1994 Sep 30;30(2):261-6.</citation>
    <PMID>7928455</PMID>
  </reference>
  <reference>
    <citation>Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Stat Med. 1994 Sep 15;13(17):1727-36.</citation>
    <PMID>7997706</PMID>
  </reference>
  <reference>
    <citation>Fechner G, Perabo FG, Schmidt DH, Haase L, Ludwig E, Schueller H, Blatter J, Mller SC, Albers P. Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. Urology. 2003 Feb;61(2):468-73.</citation>
    <PMID>12597983</PMID>
  </reference>
  <reference>
    <citation>Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):665-72.</citation>
    <PMID>14529770</PMID>
  </reference>
  <reference>
    <citation>Herman JM, Smith DC, Montie J, Hayman JA, Sullivan MA, Kent E, Griffith KA, Esper P, Sandler HM. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004 Jul;64(1):69-73.</citation>
    <PMID>15245938</PMID>
  </reference>
  <reference>
    <citation>Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, Colardelle F, Brunel P, Baillet F. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993 Nov;11(11):2150-7.</citation>
    <PMID>8229129</PMID>
  </reference>
  <reference>
    <citation>Kent E, Sandler H, Montie J, Lee C, Herman J, Esper P, Fardig J, Smith DC. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol. 2004 Jul 1;22(13):2540-5.</citation>
    <PMID>15226322</PMID>
  </reference>
  <reference>
    <citation>Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, Allouache N, Bachaud JM, Chevreau C, Kramar A, Chauvet B; Study Group on Genito-Urinary Tumors. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):172-8. doi: 10.1016/j.ijrobp.2009.10.038. Epub 2010 Apr 10.</citation>
    <PMID>20385453</PMID>
  </reference>
  <reference>
    <citation>Lawrence TS, Chang EY, Hahn TM, Shewach DS. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). Clin Cancer Res. 1997 May;3(5):777-82.</citation>
    <PMID>9815749</PMID>
  </reference>
  <reference>
    <citation>Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997 Dec;15(12):3441-5.</citation>
    <PMID>9396395</PMID>
  </reference>
  <reference>
    <citation>Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M, Schrott KM, Sauer R. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002 Jul 15;20(14):3061-71.</citation>
    <PMID>12118019</PMID>
  </reference>
  <reference>
    <citation>Sangar VK, McBain CA, Lyons J, Ramani VA, Logue JP, Wylie JP, Clarke NW, Cowan RA. Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):420-5.</citation>
    <PMID>15667962</PMID>
  </reference>
  <reference>
    <citation>Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res. 1994 Jun 15;54(12):3218-23.</citation>
    <PMID>8205542</PMID>
  </reference>
  <reference>
    <citation>Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM; Radiation Therapy Oncology Group. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003 Apr 15;97(8 Suppl):2115-9. Review.</citation>
    <PMID>12673704</PMID>
  </reference>
  <reference>
    <citation>Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997 Nov;15(11):3394-8.</citation>
    <PMID>9363871</PMID>
  </reference>
  <reference>
    <citation>Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner DG. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001 Feb 1;19(3):666-75.</citation>
    <PMID>11157016</PMID>
  </reference>
  <reference>
    <citation>Tester W, Caplan R, Heaney J, Venner P, Whittington R, Byhardt R, True L, Shipley W. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996 Jan;14(1):119-26.</citation>
    <PMID>8558186</PMID>
  </reference>
  <reference>
    <citation>Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003 Jun 7;361(9373):1927-34. Review.</citation>
    <PMID>12801735</PMID>
  </reference>
  <reference>
    <citation>Vogelzang NJ, Stadler WM. Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 1999 Feb;53(2):243-50. Review.</citation>
    <PMID>9933034</PMID>
  </reference>
  <reference>
    <citation>von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068-77.</citation>
    <PMID>11001674</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2011</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder cancer</keyword>
  <keyword>Organ-conserving strategy</keyword>
  <keyword>Radiochemotherapy</keyword>
  <keyword>non metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

